Isaralgagene civaparvovec

西哌艾萨基

Report date: 2025/11/24 15:25:55

Base Information

Drug NameIsaralgagene civaparvovec
Drug Alias NameST-920
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV6 vector
Mechanisms of ActionGene transferenceα-Galactosidase stimulants
Targetsα-Galactosidase
Therapy Area/IndicationsFabry Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[7] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesSangamo Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSangamo Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsFabry Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A